Cargando…
Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
AIMS/INTRODUCTION: This study aimed to investigate whether insulin resistance (IR) in individuals with type 2 diabetes undergoing intensive glycemic control determines the extent of improvement in neuropathy. MATERIALS AND METHODS: This was an exploratory substudy of an open‐label, randomized contro...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565403/ https://www.ncbi.nlm.nih.gov/pubmed/34002953 http://dx.doi.org/10.1111/jdi.13582 |
_version_ | 1784593819480621056 |
---|---|
author | Ponirakis, Georgios Abdul‐Ghani, Muhammad A Jayyousi, Amin Zirie, Mahmoud A Al‐Mohannadi, Salma Almuhannadi, Hamad Petropoulos, Ioannis N Khan, Adnan Gad, Hoda Migahid, Osama Megahed, Ayman Qazi, Murtaza AlMarri, Fatema Al‐Khayat, Fatima Mahfoud, Ziyad DeFronzo, Ralph Malik, Rayaz A |
author_facet | Ponirakis, Georgios Abdul‐Ghani, Muhammad A Jayyousi, Amin Zirie, Mahmoud A Al‐Mohannadi, Salma Almuhannadi, Hamad Petropoulos, Ioannis N Khan, Adnan Gad, Hoda Migahid, Osama Megahed, Ayman Qazi, Murtaza AlMarri, Fatema Al‐Khayat, Fatima Mahfoud, Ziyad DeFronzo, Ralph Malik, Rayaz A |
author_sort | Ponirakis, Georgios |
collection | PubMed |
description | AIMS/INTRODUCTION: This study aimed to investigate whether insulin resistance (IR) in individuals with type 2 diabetes undergoing intensive glycemic control determines the extent of improvement in neuropathy. MATERIALS AND METHODS: This was an exploratory substudy of an open‐label, randomized controlled trial of individuals with poorly controlled type 2 diabetes treated with exenatide and pioglitazone or insulin to achieve a glycated hemoglobin <7.0% (<53 mmol/mol). Baseline IR was defined using homeostasis model assessment of IR, and change in neuropathy was assessed using corneal confocal microscopy. RESULTS: A total of 38 individuals with type 2 diabetes aged 50.2 ± 8.5 years with (n = 25, 66%) and without (n = 13, 34%) IR were studied. There was a significant decrease in glycated hemoglobin (P < 0.0001), diastolic blood pressure (P < 0.0001), total cholesterol (P < 0.01) and low‐density lipoprotein (P = 0.05), and an increase in bodyweight (P < 0.0001) with treatment. Individuals with homeostasis model assessment of IR <1.9 showed a significant increase in corneal nerve fiber density (P ≤ 0.01), length (P ≤ 0.01) and branch density (P ≤ 0.01), whereas individuals with homeostasis model assessment of IR ≥1.9 showed no change. IR was negatively associated with change in corneal nerve fiber density after adjusting for change in bodyweight (P < 0.05). CONCLUSIONS: Nerve regeneration might be limited in individuals with type 2 diabetes and IR undergoing treatment with pioglitazone plus exenatide or insulin to improve glycemic control. |
format | Online Article Text |
id | pubmed-8565403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85654032021-11-09 Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control Ponirakis, Georgios Abdul‐Ghani, Muhammad A Jayyousi, Amin Zirie, Mahmoud A Al‐Mohannadi, Salma Almuhannadi, Hamad Petropoulos, Ioannis N Khan, Adnan Gad, Hoda Migahid, Osama Megahed, Ayman Qazi, Murtaza AlMarri, Fatema Al‐Khayat, Fatima Mahfoud, Ziyad DeFronzo, Ralph Malik, Rayaz A J Diabetes Investig Articles AIMS/INTRODUCTION: This study aimed to investigate whether insulin resistance (IR) in individuals with type 2 diabetes undergoing intensive glycemic control determines the extent of improvement in neuropathy. MATERIALS AND METHODS: This was an exploratory substudy of an open‐label, randomized controlled trial of individuals with poorly controlled type 2 diabetes treated with exenatide and pioglitazone or insulin to achieve a glycated hemoglobin <7.0% (<53 mmol/mol). Baseline IR was defined using homeostasis model assessment of IR, and change in neuropathy was assessed using corneal confocal microscopy. RESULTS: A total of 38 individuals with type 2 diabetes aged 50.2 ± 8.5 years with (n = 25, 66%) and without (n = 13, 34%) IR were studied. There was a significant decrease in glycated hemoglobin (P < 0.0001), diastolic blood pressure (P < 0.0001), total cholesterol (P < 0.01) and low‐density lipoprotein (P = 0.05), and an increase in bodyweight (P < 0.0001) with treatment. Individuals with homeostasis model assessment of IR <1.9 showed a significant increase in corneal nerve fiber density (P ≤ 0.01), length (P ≤ 0.01) and branch density (P ≤ 0.01), whereas individuals with homeostasis model assessment of IR ≥1.9 showed no change. IR was negatively associated with change in corneal nerve fiber density after adjusting for change in bodyweight (P < 0.05). CONCLUSIONS: Nerve regeneration might be limited in individuals with type 2 diabetes and IR undergoing treatment with pioglitazone plus exenatide or insulin to improve glycemic control. John Wiley and Sons Inc. 2021-06-19 2021-11 /pmc/articles/PMC8565403/ /pubmed/34002953 http://dx.doi.org/10.1111/jdi.13582 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Ponirakis, Georgios Abdul‐Ghani, Muhammad A Jayyousi, Amin Zirie, Mahmoud A Al‐Mohannadi, Salma Almuhannadi, Hamad Petropoulos, Ioannis N Khan, Adnan Gad, Hoda Migahid, Osama Megahed, Ayman Qazi, Murtaza AlMarri, Fatema Al‐Khayat, Fatima Mahfoud, Ziyad DeFronzo, Ralph Malik, Rayaz A Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control |
title | Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control |
title_full | Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control |
title_fullStr | Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control |
title_full_unstemmed | Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control |
title_short | Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control |
title_sort | insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565403/ https://www.ncbi.nlm.nih.gov/pubmed/34002953 http://dx.doi.org/10.1111/jdi.13582 |
work_keys_str_mv | AT ponirakisgeorgios insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT abdulghanimuhammada insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT jayyousiamin insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT ziriemahmouda insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT almohannadisalma insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT almuhannadihamad insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT petropoulosioannisn insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT khanadnan insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT gadhoda insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT migahidosama insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT megahedayman insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT qazimurtaza insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT almarrifatema insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT alkhayatfatima insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT mahfoudziyad insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT defronzoralph insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol AT malikrayaza insulinresistancelimitscornealnerveregenerationinpatientswithtype2diabetesundergoingintensiveglycemiccontrol |